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Background: Schizotypy, or the set of personality traits related to schizophrenia, is considered an endophenotypic
manifestation that is more represented in first-degree relatives of patients with schizophrenia than in the general
population. The assessment of schizotypy is primarily based on self-reports, and for this reason it presents several
limitations. In order to assess schizotypy, this study proposes a diagnostic instrument based on clinical reports.
Methods: A sample of 66 subjects, composed of 25 outpatients with schizophrenia, 18 siblings of these patients
and 23 healthy controls, was subjected to the personality assessment test SWAP-200 by trained clinical interviewers.
To test the hypothesis of the difference between the profiles of the Personality Disorders within the schizophrenia
spectrum, a Multivariate Analysis of Variance and subsequent planned comparisons were conducted.
Results: Patients with schizophrenia scored higher than both their siblings and the controls on all SWAP-200 scales;
their siblings, compared to the healthy controls, showed significant statistical differences, with higher mean scores
for paranoid (F(1,63) = 7.02; p = 0.01), schizoid (F(1,63) = 6.56; p = 0.013) and schizotypal (F(1,63) = 6.47; p = 0.013) traits
(PD T scores of Cluster A and Q-factor scores for the schizoid scale [F(1,63) = 6.47; p = 0.013]).
Conclusions: Consistent with previous data, first-degree relatives of patients with schizophrenia scored higher on
schizophrenia-related personality traits than a general population comparison sample. SWAP-200, as an alternative
diagnostic instrument to self-report measures, is able to reveal the higher prevalence of schizotypal traits in siblings
of patients with schizophrenia, suggesting its possible use as a complementary instrument for the assessment of
schizophrenia.
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Evidence from adoption, twin, and family studies has
shown the importance of genetics in the aetiology of
psychosis [1,2].
Data from these studies suggest that genetic vulner-
ability to developing schizophrenia is present in first-
degree relatives of patients with schizophrenia [3], in
whom there is a greater genetic risk for psychotic transi-
tion than in the general population. Furthermore, this* Correspondence: mariachiara.torti@uniroma1.it
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reproduction in any medium, provided the orgenetic liability can produce “schizophrenia-like” traits
(e.g., suspiciousness, eccentricity, social isolation/with-
drawal) in these family members, even in the absence of
an overt psychotic disorder [4].
The identification of these subthreshold symptoms
that genetically correlate with the risk of schizophrenia,
which we may term as its endophenotype [1], would be
extremely informative for a better understanding of the
underlying mechanisms of the illness process of schizo-
phrenia spectrum disorders, as well as for the detection
of the involved genes (i.e. “endophenotype strategy” [5]).
Schizophrenia-related personality traits are part of this
endophenotype [6].d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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assessed personality traits are expressed under partial
genetic control; an example is the evidence of heritability
for the standard MMPI scales, estimated between 0.26
and 0.61 (mean = 43.4) [7].
These personality traits, which are more prevalent
among the relatives of patients with schizophrenia, con-
stitute the overall expression of the concept of “schizo-
typy” [8,9].
According to Meehl [10,11], these subclinical
schizophrenia-like characteristics, when observed in
relatives of psychotic subjects, represent manifestations
of the interaction between an inherited “integrative
neural defect” predisposing to schizophrenia, termed
“schizotaxia”, and the environmental experience of that
particular individual. The typical outcome of this inter-
action is a specific personality organization, which ex-
presses a proneness to develop psychosis, characterized
by traits previously described by Kraepelin [12] and
Bleuler [13], i.e., interpersonal aversiveness, anhedonia,
ambivalence, and cognitive slippage. After Rado [14],
Meehl indicated this syndrome as “schizotypy” and the
affected individuals as “schizotypal”. He theorized that
schizotaxic individuals will manifest schizotypy on a
dynamic continuum of increasing severity, which ranges
from relative psychological health to full-blown schizo-
phrenia, passing through subclinical degrees of deviance
and overt personality disorders. According to this dimen-
sional perspective of Meehl’s schizotaxia-schizotypy para-
digm, although a subgroup of schizotaxics can develop
schizophrenia, schizotypy is the most typical manifestation
of predisposition to the inherited schizophrenia.
Subsequent investigations have shown that symptoms
of Schizotypal Personality Disorder reflect increasing
degrees of manifestation of schizotypy, in the sense of a
“latent personality organization” in schizotaxic individuals
[11,14]. Moreover, there is evidence that a detectable
Schizotypal Personality Disorder may be particularly use-
ful for enhancing detection of genes contributing to the
risk of schizophrenia [15]. These observations have con-
firmed that patients with Schizotypal Personality Disorder
often have a family history of schizophrenia, and that chil-
dren of mothers with schizophrenia are more likely to de-
velop schizophrenia or schizotypal disorder.
In fact, although several Personality Disorders have been
associated with susceptibility to schizophrenia, such as
Paranoid Personality Disorder [16-18], Schizoid Personal-
ity Disorder and Avoidant Personality Disorder [17], the
one most often related to schizophrenia is Schizotypal
Personality Disorder [15,16,19-21].
Schizotypal Personality Disorder, according to DSM-
IV-TR criteria, is hereditary, and has an estimated
incidence between 4.2% and 14.6% [18,22] among adult,
non-psychotic first-degree relatives of patients withschizophrenia, compared to 2-3% of the general popula-
tion [23].
Therefore, since research has indicated schizotypy as a
genetic pool from which cases of schizophrenia may
arise, a wide range of questionnaires has been developed
with the aim of psychometrically detecting people prone
to psychosis (see, among others, the positive and nega-
tive scales developed by the research team of the Univer-
sity of Wisconsin [24,25], the Schizophrenia Proneness
Scale of the MMPI-2 (SzP) [26] and the Schizotypal Per-
sonality Questionnaire (SPQ) [27]). However, the tools
currently available that enable clinicians to assess schizo-
typy are based on a format of direct questioning that
may be inappropriate. Moreover, some of these tools are
also designed specifically to meet the current DSM-IV
categories and criteria, limiting their usefulness in mak-
ing significant revisions to these criteria. Furthermore, as
these assessments of schizotypy take a long time and can
only be performed by qualified and experienced inter-
viewers, researchers have often used self-report measures
as indicators of the risk of developing schizophrenia or
psychosis.
Self-report measures, with a few exceptions, proved to
be less effective than interviews in distinguishing rela-
tives of patients with schizophrenia from healthy control
subjects [28,29]. Several explanations for these findings
have been proposed. Some studies have shown a defen-
sive attitude by relatives in answering self-report ques-
tions assessing schizotypy, so to deny psychopathology
[30,31]. In our opinion, it is necessary to consider this
defensive attitude towards schizotypy questionnaires, in
order to avoid diagnostic bias.
Compared to interview-based evaluations, self-report
questionnaires are less sensitive to specific schizotypal
traits in relatives of patients, especially social skills deficits
and, probably, odd behavior. Moreover, most self-report
assessments evaluate only a few aspects of schizotypy, not
referring specifically to those characteristics that family
studies have found to be prevalent in relatives of patients
with schizophrenia. Finally, these self-report tools do not
evaluate the multidimensional aspects of schizotypy or all
DSM-IV criteria [28].
These concerns suggest the need for alternative solu-
tions to assess schizotypy.
This work adds to several studies that have previously
investigated schizotypal personality traits, conceived as
subthreshold manifestations, genetically related to schizo-
phrenia, in healthy relatives of patients with schizophrenia
[32-34]; however, the originality of this study lies in the fact
that a different perspective is proposed, i.e., the direct ob-
servation by experienced clinicians, rather than self-report
tools. Therefore, the instrument for personality assessment
chosen for the present study is the Shedler-Westen Assess-
ment Procedure (SWAP-200), which differs from other
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was designed for use by expert clinical raters. Thus,
SWAP-200 is completed by mental health professionals,
typically licensed psychiatrists or psychologists, and not by
patients or clients.
The aim of this study is to compare personality traits
of patients with schizophrenia, non-psychotic siblings of
these patients and healthy controls, using SWAP-200, in
order to:
1) Evaluate personality traits related to Cluster A in
non-psychotic siblings of included patients.
2) In particular, target the continuum of liability below
the threshold of psychosis by evaluating whether
mean scores on the scales related to these traits are
found in siblings of patients midway between the
scores of patients and those of healthy controls
(lower than the scores of patients but higher than
those of the controls), and if the observed
differences have statistical significance.
Methods
Ethics
The study was approved by the Ethics Committee for
Medical Research (reference number 2333/09.02.2012;
prot. 104/12), Policlinico Umberto I° Hospital, Rome, Italy.
Assessment instruments
The diagnostic test used in this study is the Shedler-
Westen Assessment Procedure 200, or SWAP-200 [35-38],
a personality assessment instrument that provides clini-
cians with a detailed and thorough description of the per-
sonality of the evaluated subjects, with a systematic and
quantifiable approach, designed to maximize both clinical
relevance and psychometric precision.
The research assessment SWAP-200 is based on the
Q-sort psychometric method [39], using a set of descrip-
tive items (Q-set) that require clinicians to arrange them
into a fixed distribution (in a defined number of groups).
This diagnostic procedure ensures diagnosis of Person-
ality Disorders (PD) both categorically and dimension-
ally, providing PD scores specifically referring to the
DSM-IV criteria, and Q scores (Q sort) empirically de-
rived and referring to the Psychodynamic Diagnostic
Manual (PDM) [40].
An experienced clinician, usually a clinical psycholo-
gist or a psychiatrist, assigns a score from 0 to 7 for each
of the 200 proposed personality-descriptive items; the
score identifies each item in a range from “not describing
the patient” to “highly describing the patient”. Descrip-
tions of personality for each patient using SWAP-200
seem to be similar to those of the Minnesota Multiphasic
Personality Inventory (MMPI), in particular, regarding the
matches between the personality profile of the patient andthe profile of the control group, except that these profiles
are not self-reports (as they are in MMPI) but rely on the
judgments of a clinician-observer.
SWAP-200 does not assume that patients can report
their maladaptive personality traits by themselves. Rather,
it presumes that a skilled clinical interviewer, through a
systematic clinical interview, or through longitudinally
knowing the patient during the period of professional con-
tact, can identify these pathological traits.
This ensures a systematic and objective assessment of
the patient, through a diagnostic instrument that evalu-
ates both the syndromal aspects and global functioning
of the patient in the context of his life.
Regarding the psychometric properties of SWAP-200,
we mention an illustrative study examining the reliability
and validity of trait scores derived from SWAP-200 via
factor analysis [41].
The study assessed the interrater reliability and validity
of the 12 SWAP-200 trait scale scores, which are compar-
able to trait dimensions assessed by self-report measures.
Interrater reliability by interview was high, with me-
dian correlations between independent interviewers of
0.82. Convergent and discriminant validity (assessed by
cross-informant correlations between the independent
interviewers and treating clinician) were also strong,
with a median convergent validity coefficient (on the di-
agonal) of r = 0.66 and a desirably low median discrimin-
ant validity coefficient (off the diagonal) of r = –0.06.
In the present study, to verify the results derived by
SWAP-200, a direct comparison between these observer-
rated data and a self-report measure was made.
This self-report assessment instrument is TALEIA
400A (Test for AxiaL Evaluation and Interview for clin-
ical, personnel, and guidance Applications), a measure
developed in Italy by Boncori and Coworkers [42] and
translated into several languages. TALEIA quantifies both
clinical and personality disorders. Its 400 items refer
mainly to specific everyday situations. Subjects are re-
quired to report the frequency of each behavioral occur-
rence on a four-level Likert-type scale (always, often,
sometimes, and never). Psychometric research on the
English translation of this instrument is in progress in the
U. S. [43]. TALEIA consists of 21 scales (18 clinical scales
based on the diagnostic criteria of DSM-IV-TR and 3 val-
idity scales). Several studies have demonstrated the validity
of this test in clinical assessment [42-45]. Furthermore,
TALEIA’s scores were compared with scores of well-
known psychopathological measures such as MMPI and
MMPI-2. The findings of these comparison studies dem-
onstrated Pearson correlation coefficients beyond the sig-
nificance level of p = 0.01.
In our research, we used the Cluster A Personality
Disorders scales Paranoid (PP), Schizoid (PSK) and
Schizotypal (PSKT).
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The participant pool for this preliminary study was com-
posed of 66 subjects: 25 outpatients with schizophrenia
(14 females, 11 males, mean age: 36.28 years ± 9.43 SD),
18 siblings of the patients with schizophrenia (6 female, 12
males, mean age: 36.78 years ± 10.87 SD) and 23 healthy
controls (12 females, 11 males, mean age: 32.26 years ±
7.61 SD).
All participants were recruited in the context of a
broader research project on endophenotypes, currently
ongoing at the Department of Neurology and Psychiatry
of Umberto I Hospital in Rome, Italy, and filled out an
informed consent form after receiving a full description
of the research project.
For several reasons, first-degree relatives of patients
with schizophrenia can differ from each other, in par-
ticular in age at recruitment and in the risk of develop-
ing schizophrenia (relative risk: parents 5%; siblings and
offspring 10%) [16]; so, in order to remove these differ-
ences, only the siblings of the schizophrenic patients en-
rolled in this study were included. Exclusion criteria
considered were neurological disorders and drug and al-
cohol dependence.
Diagnosis of schizophrenia, in the patient group, was
made by three expert psychiatrists (MCT, FDF, AM),
according to DSM-IV criteria [46]. All patients, our
outpatient-service clients for at least two years, were be-
ing treated with second-generation antipsychotic drugs
at the time of the study and were in a phase of psycho-
pathological stability, with minimal or no florid symp-
toms. Their social functioning was sufficiently preserved
to allow an effective interaction with the clinicians.
Siblings of patients with schizophrenia and healthy
controls did not differ on socio-demographic variables,
and were screened with the SCID-I/NP (Non-Patient
Edition) [47] to exclude psychotic disorders.
Procedure
All participants were interviewed by three psychiatrists
(MCT, AM, FDF) and a clinical psychologist (AB).
These four raters, all with at least three years of clinical
experience after their specialization degrees, underwent
training in the use of SWAP-200; at the conclusion of the
training, a full recorded semi-structured interview of an
unknown patient was submitted to them. Raters were
asked to provide scores for every item. The analysis of the
interrater-reliability was assessed by a bivariate correlation
obtaining an acceptable index of agreement (r = 0.74).
For siblings and healthy controls, socio-demographic
data like gender, age, education and marital status were
collected through an interview at the beginning of the
study. Patient data were derived through a review of
their medical records. Healthy participants were evalu-
ated with SCID-I/NP. All subjects filled out the TALEIAquestionnaire. Thereafter, all participants were evaluated
with SWAP-200 through at least three clinical interviews
lasting roughly two hours each.
In these interviews, as in typical clinical practice, clini-
cians look to subjects’ narratives about their daily lives
and to observed behavior in interaction with the inter-
viewer. In particular, the survey focuses on their symp-
toms, their education and work history, and their
relationships, requiring examples of emotionally salient
experiences. From these data, the clinicians make judg-
ments about the ways the subjects characteristically
think, feel, view self and others, regulate impulses and
behave in significant relationships, consistently assigning
a score to the items.
This suggests that the extensive knowledge of the sub-
ject SWAP-200 requires allows the clinician to immedi-
ately detect the presence of psychopathology, preventing
the execution of the interview by interviewers blind to
diagnosis. For this reason, in the present work as in pre-
vious studies, this procedure was carried out as an open
label study.
Statistical analysis
Data were processed and analyzed using SPSS for Win-
dows, version 19.0.
To test the hypothesis that PD scores of SWAP-200 in
at least two groups of subjects were significantly differ-
ent, the Multivariate Analysis of Variance (MANOVA)
was used. This kind of analysis consists of an independ-
ent variable with three levels, which are the Patient
Group, the Siblings Group and the Healthy Controls
Group, and of four dependent variables, namely, the
Cluster A Personality Disorders scale and the High
Functioning scale of SWAP-200. The analysis was re-
peated using the same independent variable and the
scores of two Q-factor scales of Personality Disorders of
schizophrenic spectrum of SWAP-200.
The analysis of the effects was assessed by Wilks’
Lamba, Pillai’s Trace, Hotelling’s Trace and Roy’s Root.
Then, the results of the multivariate planned compari-
sons between the Patients group vs. the Siblings group,
and the Siblings group vs. the Healthy Control group
were analyzed, as were the effects of the univariate com-
parisons between the same groups.
For the analysis of the multivariate and univariate ef-
fects and of the planned comparisons, the significance
level was set at p < 0.05.
To correlate the scales of SWAP-200 with the scales of
TALEIA, bivariate correlations with the Pearson correl-
ation coefficient were made.
Results
Before the application of multivariate tests, assumptions
of normality of the distributions of the independent
Table 1 Estimated marginal means for PD scales
Dependent
variable





PD T Para Patients 48.772 1.414 45.945 51.599
Siblings 42.896 1.667 39.565 46.227
Controls 37.000 1.475 34.053 39.947
PD T Sch Patients 60.038 1.479 57.084 62.993
Siblings 42.589 1.742 39.107 46.071
Controls 36.630 1.541 33.550 39.711
PD T Szt Patients 65.634 1.517 62.603 68.665
Siblings 42.459 1.788 38.887 46.031
Controls 36.566 1.581 33.406 39.726
PD T HF Patients 46.722 1.448 43.828 49.616
Siblings 64.527 1.707 61.116 67.937
Controls 69.766 1.510 66.748 72.783
Torti et al. BMC Psychiatry 2013, 13:245 Page 5 of 9
http://www.biomedcentral.com/1471-244X/13/245variables considered in the analysis were evaluated; the
indices of skewness and kurtosis ranged between 1 and -1.
Due to this, the values in this range indicate that non-
normality is not a source of serious distortions [48].
Levene’s Test of Equality of Error variances was not
significant for any independent variable, thus verifying the
assumption of homoschedasticity of variances.
To test the difference between groups considered in
PD scale for the Cluster A of SWAP-200 multivariate ana-
lysis of variance was performed, and showed that the
Groups Effect was significant, (Wilk’s Lambda(4,60) < .001;
p < 0.001): this result underlines that at least two groups
are different in the scores for Personality Disorders and
High Functioning, considered as a whole. Pursuing the
analysis of the univariate tests for the effects between sub-
jects, all the considered scales showed statistical signifi-










Figure 1 Estimated marginal means for the scores of the PD T scalesthe multivariate planned comparisons, the first (Patients
vs. Siblings) was significant (Wilk’s Lambda(4,60) = 0.389;
p < 0.001); the analysis of the results of univariate planned
comparisons for the Cluster A Personality Disorders
scales showed significant differences (Pa F(1,63) = 7.224
p = 0.009; Sch F(1,63) = 58.31 p < 0.001; Szt F(1,63) = 97.721
p < 0.001), similarly to the High Functioning scale (HF)
(F(1,63) =63.28).
The multivariate comparison of Siblings vs. Healthy
Controls was significant (Wilk’s Lambda(4,60) = 0.848;
p = 0.039); in deepening the analysis of the results of
univariate planned comparisons, it showed statistically
significant differences (PD Para, F(1,63) = 7.02 p = 0.01;
PD Sch, F(1,63) = 6.56 p = 0.013; PD Szt, F(1,63) = 6.1 p = 0.016;
HF, F(1,63) = 5.30).
The statistical hypothesis test of the difference be-
tween groups considered in Q-factor scale of SWAP-200
was significant (Wilk’s Lambda(2,62) = 0.11; p < 0.001);
this meant that at least two groups considered in the
Schizophrenia Spectrum scale of Q-factor scale of
SWAP-200 test were different.
Considering the results of the univariate compari-
sons for effects between subjects, it was noted that
the difference was statistically significant for the two
Q-factor scales Schizoid (F(2,63) = 73.94; p < 0.001) and
Paranoid (F(2,63) = 3.22; p = 0.046). The first multivariate
planned comparison (Patients vs. Siblings) was significant
(Wilk’s Lambda(2,62) = 0.465; p < 0.001). The analysis of the
univariate results of the first planned comparison
showed significant differences for the Q-factor scale
Schizoid (F(1,63) = 69.04; p < 0.001), but not for Paranoid
(F(1,63) = 0.773; p = 0.383). Also, the multivariate compari-
son between Siblings vs. Healthy Controls was significant
(Wilk’s Lambda(2,62) = 0.868; p = 0.013). The analysis of the
univariate planned comparisons showed a significant dif-
ference only for the Q-factor scale Schizoid (F(1,63) = 6.47;




of cluster A in the three groups.
Table 3 Matrix of bivariate correlations between the
considered scales of SWAP-200 and the cluster A scales
of TALEIA
PP PSK PSKT
PD T Para Pearson’s r .531** .271 .396*
Sig. (2-tailed) .003 .140 .030
N 66 66 66
PD T Sch Pearson’s r .427* .401* .467**
Sig. (2-tailed) .019 .025 .009
N 66 66 66
PD T Szt Pearson’s r .523** .446* .549**
Sig. (2-tailed) .003 .012 .002
N 66 66 66
Q T Sc Pearson’s r .426* .390* .467**
Sig. (2-tailed) .019 .030 .009
N 30 31 30
Q T Pa Pearson’s r .466** .206 .318
Sig. (2-tailed) .010 .266 .087
N 66 66 66
**The correlation is significant at p 0.01 (2-tailed).
*The correlation is significant at p 0.05 (2-tailed).
Notes:
for PD scales of SWAP-200: Para = Paranoid; Sch = Schizoid; Szt = Schizotypal;
HF = High Functioning.
for Q factor scales of SWAP-200: Sc = Schizoid; Pa = Paranoid.
for Cluster A scales of TALEIA: PP = Paranoid; PSK = Schizoid; PSKT = Schizotypal.
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the PD T scales considered in our analysis, the Patient
group scored significantly higher than the Siblings group
on the Personality Disorders scales in the first compari-
son (Patients vs. Siblings), while on the High Function-
ing scale the Siblings group scored higher than the
Patients group; in the second planned comparison of PD
T scale scores (Siblings vs. Healthy Controls), the Sib-
lings group scored significantly higher on the Personality
Disorder scale than Healthy Controls, while on the High
Functioning scale, the Healthy Control group scored
higher than the Siblings group. The estimated marginal
means for PD T scale scores related to Cluster A Person-
ality Disorders for all three groups are summarized in
Figure 1.
For the analysis of the planned comparisons of Q-
factor scales considered in our study, the Patient group
scored higher than the Siblings group on the Schizoid
Q-factor scale (estimated marginal means for the first
comparison, i.e., Patients vs. Siblings), while in the sec-
ond planned comparison (Siblings vs. Healthy Controls),
the Siblings group scored significantly higher than the
Healthy Control group on the same scale (Table 2).
As expected (and shown in Table 3), the scales of
SWAP-200 and TALEIA for the same constructs showed
positive and statistically significant correlations (Paranoid
N = 66, r = 0.531 p < 0.01; Schizoid N = 66, r = 0.401
p < 0.05; Schizotypal N = 66, r= 0.549 p < 0.01), highlighting
a notable concurrent validity of SWAP-200.
The significant correlations between the Cluster A
scales of TALEIA and the not homonymous PD T scales
can be explained by the fact that some indicators of the
Cluster A scales are overlapped.
The Q-factor scale Schizoid showed positive correla-
tions with all the considered scales of TALEIA (Paranoid
N = 66, r = 0.426 p < 0.05; Schizoid N = 66, r = 0.390
p < 0.05; Schizotypal N = 66, r = 0.467 p < 0.01) but
the Q-factor scale Paranoid showed positive correla-
tions only with the Paranoid scale of TALEIA (N = 66,
r = 0.466 p < 0.01).Table 2 Estimate marginal means for Q factor scales
Dependent
variable





Q T Sc Patients 64.103 1.571 60.964 67.241
Siblings 43.933 1.851 40.235 47.632
Controls 37.647 1.637 34.375 40.919
Q T Pa Patients 46.346 1.401 43.547 49.145
Siblings 44.443 1.651 41.144 47.741
Controls 41.240 1.460 38.321 44.158The Q-factor Schizoid includes the DSM-IV diagnosis
of Schizotypal, Schizoid and Avoidant Personality Dis-
order, recognized as difficult to distinguish.
The results of the Q-analysis from previous studies by
the authors of the methodology SWAP denote a lack of
clear boundary lines between these three categories,
confirmed by the results from the analysis of correla-
tions in our research.
This element could explain the first set of significant
correlations between the scales of TALEIA and the Q-
factor Schizoid.
Discussion and conclusion
As an alternative to self-reports, we used SWAP-200 in
this preliminary study to assess schizotypy.
Our preliminary results are consistent with previous
data supporting the higher prevalence of schizotypal traits
in first-degree relatives of patients with schizophrenia
compared to the general population [15,19-21,34].
In particular, analyzing our data we may observe that:
1. In the items that meet the criteria for Cluster A
Personality Disorders of DSM-IV, siblings of patients
with schizophrenia show significant differences
compared to healthy controls, with higher scores for
paranoid, schizoid and schizotypal traits.
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DSM-IV Cluster A of Personality Disorders, it is
possible to note that the scores of the scales
considered for the Siblings group are intermediate
between the scores of the other two groups, showing
statistically significant differences not only compared
to the Patient group, as expected, but also compared
to the Healthy Control group. This element is
prominent because the scores for paranoid, schizoid
and schizotypal traits of siblings are significantly
lower than the scores for the same traits of patients
with schizophrenia, but are significantly higher than
those obtained by the healthy controls.2. In the items that meet criteria for the P Axis of the
PDM for the evaluation of personality patterns and
Personality Disorders, these significant differences are
reconfirmed for the schizoid scale.
These data were also confirmed by the analysis of Q-
scores, hence showing validity also in the context of a
different taxonomy.
Regarding the Q-factor scores on the schizoid scale,
our analysis revealed a tendency of the Siblings group to
score midway between the Patient group and the Healthy
Control group. Compared to patients with schizophrenia,
siblings scored significantly lower on schizoid scale, but
compared to the Healthy Control group, the Siblings
group confirmed the trend to score significantly higher.
For the Q-factor Paranoid scale, the differences between
the three groups were not significant, but the usual trend
of the Siblings group to score higher than Healthy Con-
trols and lower than Patients, was confirmed.
The analysis of correlations with the self-report tool
confirmed reliability and validated what the external
raters observed.
Based on data presented in this study, we may conclude
that SWAP-200, similarly to self-report measures, is able
to accurately highlight the presence of schizotypal traits in
first-degree relatives of patients with schizophrenia,
according to both the DSM-IV categorical diagnostic ap-
proach and the dimensional model proposed by PDM.
Clinicians have often proposed to replace the current
diagnostic assessment for Personality Disorders with di-
mensional models [35]. These proposed models derive
their data mainly from self-report issues. A different ap-
proach is to derive personality dimensions from data
provided by expert clinicians.
In addition to developing a diagnostic tool, the authors
of the methodology SWAP have tried to introduce a
new way of understanding personality assessment: they
have combined categorical and descriptive logic to a di-
mensional approach, integrating scientific rigor with
clinical utility.In a dimensional approach, the assessment is not car-
ried out by defining the presence or absence of specific
traits, but by considering how strongly they arise or
come close to the diagnostic prototype.
In this sense, SWAP-200 is particularly suitable to detect
subthreshold manifestations of schizotypy and for tracking
disease susceptibility in non-clinical genetic carriers.
Besides the implication for the validity of the
schizophrenia-spectrum paradigm, our results suggest
the clinical importance of a dimensional diagnosis for
refining the identification of spectrum phenotypes both
in genetic research and in early detection.
Literature has already confirmed the reliability and the
validity of SWAP-200 as a predictor of maladaptive
traits, such as suicide attempts and previous psychiatric
hospitalizations, and of global functioning, clinical diag-
nosis, pathological development variables, and medical
history [49,50], hence contributing to the collection of
information consistent with the patient’s development,
outcome, and global functioning.
Based on these results, we propose SWAP-200 also as
a diagnostic instrument to detect schizotypal personality
traits, as well as for a complete evaluation of the global
profile of the patient.
Limitations of the study
This study has two key limitations:
First, selection “bias” may have resulted from the
possibility that the siblings willing to enroll in studies
of this type have personality traits associated with
better functioning and volunteer motivation.
The second limitation is that the sample size is
relatively small (less than 30 subjects per group).
Future research in larger samples, preferably carried
out with both SWAP-200 and other self-rated tools
(i.e. SCID II; 16PF; MCMI-III), may address the above
limitation.
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